4 research outputs found

    Weak signals in Science and Technologies 2019: Analysis and recommendations: Technologies at a very early stage of development that could impact the future

    Get PDF
    JRC has developed a quantitative methodology to detect very early signs of emerging technologies, so called "weak signals of technology development". Using text mining and scientometric indicators, 256 of these weak signals have been identified on the basis of scientific literature and have been reported earlier this year in a JRC technical report. The purpose of this follow-up report is to provide a European perspective and to provide recommendations for policy makers. Europe shows vulnerabilities in 179 of these weak signals, further analysed in the present report.JRC.I.3-Text and Data Minin

    Weak signals in Science and Technologies: 2019 Report

    Get PDF
    JRC has developed a quantitative methodology to detect very early signs of emerging technologies, so called "weak signals of technology development". Using text mining and scientometrics indicators, 257 of these weak signals have been identified on the basis of scientific literature and are reported in the present report.JRC.I.3-Text and Data Minin

    Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure

    No full text
    BACKGROUND The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function in patients with heart failure with a reduced ejection fraction. Its effect on cardiovascular outcomes is unknown. METHODS We randomly assigned 8256 patients (inpatients and outpatients) with symptomatic chronic heart failure and an ejection fraction of 35% or less to receive omecamtiv mecarbil (using pharmacokinetic-guided doses of 25 mg, 37.5 mg, or 50 mg twice daily) or placebo, in addition to standard heart-failure therapy. The primary outcome was a composite of a first heart-failure event (hospitalization or urgent visit for heart failure) or death from cardiovascular causes. RESULTS During a median of 21.8 months, a primary-outcome event occurred in 1523 of 4120 patients (37.0%) in the omecamtiv mecarbil group and in 1607 of 4112 patients (39.1%) in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.86 to 0.99; P = 0.03). A total of 808 patients (19.6%) and 798 patients (19.4%), respectively, died from cardiovascular causes (hazard ratio, 1.01; 95% CI, 0.92 to 1.11). There was no significant difference between groups in the change from baseline on the Kansas City Cardiomyopathy Questionnaire total symptom score. At week 24, the change from baseline for the median N-terminal pro-B-type natriuretic peptide level was 10% lower in the omecamtiv mecarbil group than in the placebo group; the median cardiac troponin I level was 4 ng per liter higher. The frequency of cardiac ischemic and ventricular arrhythmia events was similar in the two groups. CONCLUSIONS Among patients with heart failure and a reduced ejection, those who received omecamtiv mecarbil had a lower incidence of a composite of a heart-failure event or death from cardiovascular causes than those who received placebo. (Funded by Amgen and others; GALACTIC-HF ClinicalTrials.gov number, NCT02929329; EudraCT number, 2016 -002299-28.)
    corecore